146 related articles for article (PubMed ID: 37970553)
1. The significance of CDT1 expression in non-cancerous and cancerous liver in cases with hepatocellular carcinoma.
Ogawa M; Moriyama M; Midorikawa Y; Nakamura H; Shibata T; Kuroda K; Nakayama H; Kanemaru K; Miki T; Sugitani M; Takayama T
J Clin Biochem Nutr; 2023 Nov; 73(3):234-248. PubMed ID: 37970553
[TBL] [Abstract][Full Text] [Related]
2. The proliferation of atypical hepatocytes and CDT1 expression in noncancerous tissue are associated with the postoperative recurrence of hepatocellular carcinoma.
Moriyama M; Kanda T; Midorikawa Y; Matsumura H; Masuzaki R; Nakamura H; Ogawa M; Matsuoka S; Shibata T; Yamazaki M; Kuroda K; Nakayama H; Higaki T; Kanemaru K; Miki T; Sugitani M; Takayama T
Sci Rep; 2022 Nov; 12(1):20508. PubMed ID: 36443564
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of
Ogawa M; Moriyama M; Nakamura H; Shibata T; Kuroda K; Sugitani M
J Clin Biochem Nutr; 2024 Mar; 74(2):169-178. PubMed ID: 38510682
[TBL] [Abstract][Full Text] [Related]
4. Involvement of proliferation of atypical hepatocytes and CDT 1 in the liver cancer of rats administered the diethylnitrosamine.
Ogawa M; Masuzaki R; Kanda T; Matsumura H; Nakamura H; Yamazaki M; Shibata T; Kogure H; Moriyama M
J Clin Biochem Nutr; 2023 Sep; 73(2):138-144. PubMed ID: 37700853
[TBL] [Abstract][Full Text] [Related]
5. CDT1 Is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.
Cai C; Zhang Y; Hu X; Hu W; Yang S; Qiu H; Chu T
Front Oncol; 2021; 11():721644. PubMed ID: 34631549
[TBL] [Abstract][Full Text] [Related]
6. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
Nakai S; Masaki T; Shiratori Y; Ohgi T; Morishita A; Kurokohchi K; Watanabe S; Kuriyama S
Int J Oncol; 2002 Apr; 20(4):769-75. PubMed ID: 11894123
[TBL] [Abstract][Full Text] [Related]
7. Paracrine effects of CCN3 from non-cancerous hepatic cells increase signaling and progression of hepatocellular carcinoma.
Li W; Liao X; Ning P; Cao Y; Zhang M; Bu Y; Lv J; Jia Q
BMC Cancer; 2019 Apr; 19(1):395. PubMed ID: 31029128
[TBL] [Abstract][Full Text] [Related]
8. BZW2, CDT1 and IVD Act As Biomarkers for Predicting Hepatocellular Carcinoma.
Jiang Z; Wei Z; Chen J; Yang F; Jiang Y; Lv L
Curr Cancer Drug Targets; 2023; 23(3):211-221. PubMed ID: 36056860
[TBL] [Abstract][Full Text] [Related]
9. Redundant and differential regulation of multiple licensing factors ensures prevention of re-replication in normal human cells.
Sugimoto N; Yoshida K; Tatsumi Y; Yugawa T; Narisawa-Saito M; Waga S; Kiyono T; Fujita M
J Cell Sci; 2009 Apr; 122(Pt 8):1184-91. PubMed ID: 19339550
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical studies on the expression of P-glycoprotein and p53 in relation to histological differentiation and cell proliferation in hepatocellular carcinoma.
Nakano A; Watanabe N; Nishizaki Y; Takashimizu S; Matsuzaki S
Hepatol Res; 2003 Feb; 25(2):158-165. PubMed ID: 12644052
[TBL] [Abstract][Full Text] [Related]
11. PCNA-associated factor (KIAA0101/PCLAF) overexpression and gene copy number alterations in hepatocellular carcinoma tissues.
Tantiwetrueangdet A; Panvichian R; Sornmayura P; Leelaudomlipi S; Macoska JA
BMC Cancer; 2021 Mar; 21(1):295. PubMed ID: 33743635
[TBL] [Abstract][Full Text] [Related]
12. Expression of the p12 subunit of human DNA polymerase δ (Pol δ), CDK inhibitor p21(WAF1), Cdt1, cyclin A, PCNA and Ki-67 in relation to DNA replication in individual cells.
Zhao H; Zhang S; Xu D; Lee MY; Zhang Z; Lee EY; Darzynkiewicz Z
Cell Cycle; 2014; 13(22):3529-40. PubMed ID: 25483089
[TBL] [Abstract][Full Text] [Related]
13. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
PeerJ; 2023; 11():e16166. PubMed ID: 37790630
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional control of DNA replication licensing by Myc.
Valovka T; Schönfeld M; Raffeiner P; Breuker K; Dunzendorfer-Matt T; Hartl M; Bister K
Sci Rep; 2013 Dec; 3():3444. PubMed ID: 24309437
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma.
Cui H; Wu F; Sun Y; Fan G; Wang Q
BMC Cancer; 2010 Jul; 10():356. PubMed ID: 20604928
[TBL] [Abstract][Full Text] [Related]
16. SIRT3 promotion reduces resistance to cisplatin in lung cancer by modulating the FOXO3/CDT1 axis.
Cao Y; Li P; Wang H; Li L; Li Q
Cancer Med; 2021 Feb; 10(4):1394-1404. PubMed ID: 33655712
[TBL] [Abstract][Full Text] [Related]
17. Characterization of conserved arginine residues on Cdt1 that affect licensing activity and interaction with Geminin or Mcm complex.
You Z; Ode KL; Shindo M; Takisawa H; Masai H
Cell Cycle; 2016 May; 15(9):1213-26. PubMed ID: 26940553
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA-PCGEM1 contributes to prostate cancer progression by sponging microRNA miR-129-5p to enhance chromatin licensing and DNA replication factor 1 expression.
Fu Q; Wang F; Yang J; Sun W; Hu Z; Xu L; Chu H; Wang X; Zhang W
Bioengineered; 2022 Apr; 13(4):9411-9424. PubMed ID: 35412947
[TBL] [Abstract][Full Text] [Related]
19. Proteolysis of DNA replication licensing factor Cdt1 in S-phase is performed independently of geminin through its N-terminal region.
Nishitani H; Lygerou Z; Nishimoto T
J Biol Chem; 2004 Jul; 279(29):30807-16. PubMed ID: 15138268
[TBL] [Abstract][Full Text] [Related]
20. Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma.
Zhang HJ; Yao DF; Yao M; Huang H; Wu W; Yan MJ; Yan XD; Chen J
World J Gastroenterol; 2012 Nov; 18(41):5897-904. PubMed ID: 23139605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
